Archivio istituzionale della ricerca dell'Università degli Studi di Palermo
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, pubblicazioni, progetti, attività) adottato dall’Università di Palermo, e ha lo scopo di raccogliere, conservare, documentare, e diffondere ad accesso aperto le informazioni relative alla produzione scientifica degli autori afferenti all’Ateneo.
EnglishPurpose: The aim of this study was to determine TP53 and NM23-H1 immunoreactivity, DNA ploidy, and S-phase fraction (SPF) in a series of 160 patients undergoing resective surgery for primary operable colorectal cancer (CRC) and to establish whether these alterations have any clinical value in predicting CRC patients' prognosis. Methods: TP53 and NM23-H1 expressions were evaluated on paraffin-embedded tissue by immunohistochemistry and DNA-ploidy and SPF on frozen tissue by flow-cytometric analysis. Results: The median follow-up time in our study group was 71 months (range 34-115 months). P53 protein expression was associated with distal tumors (P < 0.05) and DNA aneuploid tumors (P < 0.05) tumors. DNA-aneuploidy was associated with distal tumors (P < 0.01), histological grade (G3) (P < 0.05), advanced Dukes' stage (C and D) (P < 0.01), lymph node metastases (P < 0.01) and high SPF (> 18.3%) (P < 0.01). The major significant predictors for both disease relapse and death were advanced Dukes' stage, DNA-aneuploidy, and high SPF, while lymphohematic invasion was the only independent factor for relapse and non-curative resection for death. Conclusions: Our results indicate that DNA aneuploidy and high SPF are associated in CRC with a poor clinical 5-year outcome, while in contrast the prognostic role of TP53 and NM23-H1 expression is still to be clarified.
Bazan V., Migliavacca M., Zanna I., Tubiolo C., Corsale S., Calo V., et al. (2002). DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 128(12), 650-658.
| Data di pubblicazione: | 2002 | |
| Titolo: | DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study | |
| Autori: | RUSSO, Antonio (Corresponding) | |
| Citazione: | Bazan V., Migliavacca M., Zanna I., Tubiolo C., Corsale S., Calo V., et al. (2002). DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 128(12), 650-658. | |
| Rivista: | ||
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1007/s00432-002-0394-6 | |
| Abstract: | Purpose: The aim of this study was to determine TP53 and NM23-H1 immunoreactivity, DNA ploidy, and S-phase fraction (SPF) in a series of 160 patients undergoing resective surgery for primary operable colorectal cancer (CRC) and to establish whether these alterations have any clinical value in predicting CRC patients' prognosis. Methods: TP53 and NM23-H1 expressions were evaluated on paraffin-embedded tissue by immunohistochemistry and DNA-ploidy and SPF on frozen tissue by flow-cytometric analysis. Results: The median follow-up time in our study group was 71 months (range 34-115 months). P53 protein expression was associated with distal tumors (P < 0.05) and DNA aneuploid tumors (P < 0.05) tumors. DNA-aneuploidy was associated with distal tumors (P < 0.01), histological grade (G3) (P < 0.05), advanced Dukes' stage (C and D) (P < 0.01), lymph node metastases (P < 0.01) and high SPF (> 18.3%) (P < 0.01). The major significant predictors for both disease relapse and death were advanced Dukes' stage, DNA-aneuploidy, and high SPF, while lymphohematic invasion was the only independent factor for relapse and non-curative resection for death. Conclusions: Our results indicate that DNA aneuploidy and high SPF are associated in CRC with a poor clinical 5-year outcome, while in contrast the prognostic role of TP53 and NM23-H1 expression is still to be clarified. | |
| Settore Scientifico Disciplinare: | Settore MED/06 - Oncologia Medica | |
| Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| Bazan2002_Article_DNAPloidyAndS-phaseFractionBut.pdf | N/A | Administrator Richiedi una copia |
Copyright © 2021